{"entity":{"id":"nct05548296","kind":"trial","name":"A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma","aka":[],"tldr":"A phase 2 trial of Gemcitabine in endometrial cancer, run by Acrivon Therapeutics, now recruiting.","summary":"A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma is a phase 2 interventional study registered as NCT05548296 by Acrivon Therapeutics, with 350 participants planned, started 2022-08-29 and due to reach its primary completion in 2027-05-30. Interventions recorded: ACR-368 and Gemcitabine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05548296","url":"https://clinicaltrials.gov/study/NCT05548296"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine"],"companies":["acrivon-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05548296","phase":"2","setting":"A Phase 2 Study of ACR-368 Therapy in Subjects With Endometrial Cancer","sponsor":"Acrivon Therapeutics","enrolled":350,"outcomes":[]},"route":"/trials/nct05548296/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"company":[{"id":"acrivon-therapeutics","kind":"company","name":"Acrivon Therapeutics","route":"/companies/acrivon-therapeutics/"}]}}